These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35714692)

  • 1. Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome.
    Li H; Guan Y; Liang B; Ding P; Hou X; Wei W; Ma Y
    Eur J Pharmacol; 2022 Aug; 928():175091. PubMed ID: 35714692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCC950 Inhibits NLRP3 Inflammasome and Alleviates Axonal Injures in Early Stages of Diffuse Axonal Injury in Rats.
    Zhao J; Guo X; Wang B; Yang Z; Huang T; Guo D; Zhang M; Song J
    Neurochem Res; 2020 Sep; 45(9):2020-2031. PubMed ID: 32474832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
    Yaw ACK; Chan EWL; Yap JKY; Mai CW
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.
    Wu D; Chen Y; Sun Y; Gao Q; Li H; Yang Z; Wang Y; Jiang X; Yu B
    Inflammation; 2020 Feb; 43(1):17-23. PubMed ID: 31646445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
    Coll RC; Hill JR; Day CJ; Zamoshnikova A; Boucher D; Massey NL; Chitty JL; Fraser JA; Jennings MP; Robertson AAB; Schroder K
    Nat Chem Biol; 2019 Jun; 15(6):556-559. PubMed ID: 31086327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
    J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
    Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
    Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
    Zhang W; Ba G; Tang R; Li M; Lin H
    Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Huang S; Chen Z; Fan B; Chen Y; Zhou L; Jiang B; Long H; Zhong W; Li X; Li Y
    J Neuroimmunol; 2021 May; 354():577543. PubMed ID: 33714750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
    Qu J; Yuan Z; Wang G; Wang X; Li K
    Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of NLRP3 inflammasome alleviates cognitive deficits in a mouse model of anti-NMDAR encephalitis induced by active immunization.
    Yang X; Sun A; Kong L; Yang X; Zhao X; Wang S
    Int Immunopharmacol; 2024 Aug; 137():112374. PubMed ID: 38851162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
    Coll RC; Robertson AA; Chae JJ; Higgins SC; Muñoz-Planillo R; Inserra MC; Vetter I; Dungan LS; Monks BG; Stutz A; Croker DE; Butler MS; Haneklaus M; Sutton CE; Núñez G; Latz E; Kastner DL; Mills KH; Masters SL; Schroder K; Cooper MA; O'Neill LA
    Nat Med; 2015 Mar; 21(3):248-55. PubMed ID: 25686105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
    Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
    Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
    Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
    Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence.
    Shi Y; Zhao L; Wang J; Liu S; Zhang Y; Qin Q
    Eur J Pharmacol; 2022 Dec; 937():175364. PubMed ID: 36336012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes.
    Bakhshi S; Shamsi S
    Int Immunopharmacol; 2022 May; 106():108595. PubMed ID: 35124417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.